Curaleaf Holdings (CURLF) Non-Current Assets (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Non-Current Assets of $2.4 billion for Q4 2025, down 4.72% year-on-year from $2.5 billion in Q4 2024, and down 4.72% on a QoQ basis from $2.5 billion in Q4 2024.
Curaleaf Holdings (CURLF) Non-Current Assets (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Non-Current Assets for 7 consecutive years, with $2.4 billion the latest figure, recorded in Q4 2025.
- Quarterly Non-Current Assets fell 4.72% year-over-year to $2.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.2 billion (down 3.27% YoY) and the FY2025 annual result came in at $2.4 billion, down 4.72% from the prior year.
- Non-Current Assets declined to $2.4 billion in Q4 2025 per CURLF's latest filing, from $2.5 billion in the prior quarter.
- Over the last five years, Non-Current Assets for CURLF reached as high as $2.8 billion in Q2 2023 and fell as low as -$974.4 billion in Q1 2022.
- A 5-year average of -$63.3 billion and a median of $2.4 billion in 2023 frame the typical range for Non-Current Assets.
- The largest YoY upside for Non-Current Assets was 23569.62% in 2022 against a maximum downside of 49767.67% in 2022.
- Year by year, Non-Current Assets stood at $10.4 million in 2021, then jumped by 23569.62% to $2.5 billion in 2022, then declined by 3.69% to $2.4 billion in 2023, then climbed by 6.08% to $2.5 billion in 2024, then fell by 4.72% to $2.4 billion in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $2.4 billion, $2.5 billion, and $2.7 billion for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.40 Bn |
| Dec 31, 2024 | 2.52 Bn |
| Sep 30, 2024 | 2.65 Bn |
| Jun 30, 2024 | 2.66 Bn |
| Dec 31, 2023 | 2.37 Bn |
| Sep 30, 2023 | 2.74 Bn |
| Jun 30, 2023 | 2.84 Bn |
| Dec 31, 2022 | 2.46 Bn |
| Sep 30, 2022 | -920.77 Mn |
| Jun 30, 2022 | -933.63 Mn |
| Mar 31, 2022 | -974.43 Bn |
| Dec 31, 2021 | 10.40 Mn |
| Sep 30, 2021 | 2.27 Bn |
| Jun 30, 2021 | 2.35 Bn |
| Mar 31, 2021 | 1.96 Bn |
| Dec 31, 2020 | 1.95 Bn |
| Sep 30, 2020 | 1.98 Bn |
| Dec 31, 2019 | 587.40 Mn |